 A multicenter Open-label, single-arm, phase III clinical trial is conducted on patients with histological stage IV Pancreatic cancer given gemcitabine plus S-1. The usefulness of this regimens as 1st line therapy for pancreatic cancer was evaluated by the disease-free survivalDFS, median survival time MST, incidence and severity of adverse event. 